Join
Live feed
·
INSIDERFilingvia Quantisnow
Contineum Therapeutics Inc. logo

Chief Scientific Officer Lorrain Daniel S. sold $54,694 worth of shares (4,170 units at $13.12) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 143,542 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CTNM· Contineum Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTNM (Contineum Therapeutics Inc.) and more on Quantisnow.